2-hydroxy-2-[4-[5-methyl-1-[2-(trifluoromethyl)-4-pyridinyl]pyrazol-3-yl]-3-oxomorpholin-2-yl]acetic acid
C16H15F3N4O5 — CID 90241666
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-hydroxy-2-[4-[5-methyl-1-[2-(trifluoromethyl)-4-pyridinyl]pyrazol-3-yl]-3-oxomorpholin-2-yl]acetic acid
2-hydroxy-2-[4-[5-methyl-1-[2-(trifluoromethyl)-4-pyridinyl]pyrazol-3-yl]-3-oxomorpholin-2-yl]acetic acid (PubChem CID 90241666) has the molecular formula C16H15F3N4O5 and a molecular weight of 400.31 g/mol. Its IUPAC name is 2-hydroxy-2-[4-[5-methyl-1-[2-(trifluoromethyl)-4-pyridinyl]pyrazol-3-yl]-3-oxomorpholin-2-yl]acetic acid.
Molecular Properties
| Compound Name | 2-hydroxy-2-[4-[5-methyl-1-[2-(trifluoromethyl)-4-pyridinyl]pyrazol-3-yl]-3-oxomorpholin-2-yl]acetic acid |
|---|---|
| PubChem CID | 90241666 |
| Molecular Formula | C16H15F3N4O5 |
| Molecular Weight | 400.31 g/mol |
| Exact Mass | 400.10 |
| IUPAC Name | 2-hydroxy-2-[4-[5-methyl-1-[2-(trifluoromethyl)-4-pyridinyl]pyrazol-3-yl]-3-oxomorpholin-2-yl]acetic acid |
| SMILES | Cc1cc(N2CCOC(C(O)C(=O)O)C2=O)nn1-c1ccnc(C(F)(F)F)c1 |
| InChI | InChI=1S/C16H15F3N4O5/c1-8-6-11(22-4-5-28-13(14(22)25)12(24)15(26)27)21-23(8)9-2-3-20-10(7-9)16(17,18)19/h2-3,6-7,12-13,24H,4-5H2,1H3,(H,26,27) |
| InChIKey | HMYTZRWVAPXSMS-UHFFFAOYSA-N |
| XLogP | 0.77 |
| TPSA | 117.78 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 400.31 |
| LogP ≤ 5 | 0.77 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 90241666 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.